1. Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma.
- Author
-
Sol N, In 't Veld SGJG, Vancura A, Tjerkstra M, Leurs C, Rustenburg F, Schellen P, Verschueren H, Post E, Zwaan K, Ramaker J, Wedekind LE, Tannous J, Ylstra B, Killestein J, Mateen F, Idema S, de Witt Hamer PC, Navis AC, Leenders WPJ, Hoeben A, Moraal B, Noske DP, Vandertop WP, Nilsson RJA, Tannous BA, Wesseling P, Reijneveld JC, Best MG, and Wurdinger T
- Subjects
- Adult, Aged, Aged, 80 and over, Algorithms, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Blood Platelets pathology, Brain Neoplasms genetics, Brain Neoplasms mortality, Brain Neoplasms surgery, Case-Control Studies, Disease Progression, Glioblastoma genetics, Glioblastoma mortality, Glioblastoma surgery, Humans, Middle Aged, Multiple Sclerosis genetics, Multiple Sclerosis pathology, Neoplasm Metastasis, RNA Splicing, RNA, Neoplasm metabolism, ROC Curve, Survival Analysis, Tumor Microenvironment genetics, Blood Platelets metabolism, Brain Neoplasms diagnosis, Glioblastoma diagnosis, Monitoring, Physiologic methods, Multiple Sclerosis diagnosis, RNA, Neoplasm genetics
- Abstract
Tumor-educated platelets (TEPs) are potential biomarkers for cancer diagnostics. We employ TEP-derived RNA panels, determined by swarm intelligence, to detect and monitor glioblastoma . We assessed specificity by comparing the spliced RNA profile of TEPs from glioblastoma patients with multiple sclerosis and brain metastasis patients (validation series, n = 157; accuracy, 80%; AUC, 0.81 [95% CI, 0.74-0.89; p < 0.001]). Second, analysis of patients with glioblastoma versus asymptomatic healthy controls in an independent validation series (n = 347) provided a detection accuracy of 95% and AUC of 0.97 (95% CI, 0.95-0.99; p < 0.001). Finally, we developed the digitalSWARM algorithm to improve monitoring of glioblastoma progression and demonstrate that the TEP tumor scores of individual glioblastoma patients represent tumor behavior and could be used to distinguish false positive progression from true progression (validation series, n = 20; accuracy, 85%; AUC, 0.86 [95% CI, 0.70-1.00; p < 0.012]). In conclusion, TEPs have potential as a minimally invasive biosource for blood-based diagnostics and monitoring of glioblastoma patients., Competing Interests: M.G.B., R.J.A.N., and T.W. are inventors on relevant patent applications. T.W. and R.J.A.N. received funding from Illumina and are shareholders of GRAIL, Inc., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF